La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Co-Diagnostics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dwight Egan

Amministratore delegato

US$1.3m

Compenso totale

Percentuale dello stipendio del CEO	29.7%
Mandato del CEO	11.4yrs
Proprietà del CEO	1.2%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dwight Egan rispetto agli utili di Co-Diagnostics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	US$1m	US$375k	-US$35m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$2m	US$366k	-US$14m
Sep 30 2022	n/a	n/a	US$15m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	US$40m
Dec 31 2021	US$2m	US$350k	US$37m
Sep 30 2021	n/a	n/a	US$42m
Jun 30 2021	n/a	n/a	US$46m
Mar 31 2021	n/a	n/a	US$51m
Dec 31 2020	US$1m	US$309k	US$42m
Sep 30 2020	n/a	n/a	US$28m
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$460k	US$275k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$474k	US$275k	-US$6m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$210k	US$195k	-US$7m

Compensazione vs Mercato: La retribuzione totale di Dwight ($USD 1.26M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 538.74K ).

Compensazione vs guadagni: La retribuzione di Dwight è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Dwight Egan (71 yo)

11.4yrs

Mandato

US$1,261,300

Compensazione

Mr. Dwight H. Egan serves as the Chairman & Chief Executive Officer and was President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment bus...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Dwight Egan	Chairman & CEO	no data	US$1.26m	1.15% $ 404.5k
Brian Brown	CFO & Company Secretary	3.6yrs	US$1.04m	0.91% $ 320.2k
Richard Abbott	President	less than a year	Nessun dato	1.85% $ 650.8k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	11.4yrs	US$237.50k	Nessun dato
David Nielsen	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Dan Bohrer	Vice President of Finance & Accounting	no data	Nessun dato	Nessun dato
Christopher Thurston	Chief Technology Officer	less than a year	Nessun dato	Nessun dato
Andrew Benson	Head of Investor Relations	no data	Nessun dato	Nessun dato
Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	no data	Nessun dato	Nessun dato
Cameron Gundry	Head of Commercialization LATAM/EUR	no data	Nessun dato	Nessun dato
Ivory Chang	Chief Regulatory Affairs Officer	1.1yrs	Nessun dato	Nessun dato
Seth Egan	Chief Commercialization Officer	less than a year	Nessun dato	Nessun dato

0.5yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di C97 non è considerato esperto (durata media 0.4 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Dwight Egan	Chairman & CEO	11.4yrs	US$1.26m	1.15% $ 404.5k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	2.5yrs	US$237.50k	Nessun dato
Richard Serbin	Independent Director	7.3yrs	US$298.00k	0.37% $ 129.4k
Carl Wittwer	Chairman of Scientific Advisory Board	2.5yrs	Nessun dato	Nessun dato
James Nelson	Independent Director	5.1yrs	US$298.00k	0.36% $ 126.7k
Noriko Kusukawa	Member of Scientific Advisory Board	2.5yrs	Nessun dato	Nessun dato
Edward Murphy	Independent Director	5.3yrs	US$298.00k	0.40% $ 140.5k
Eugene Durenard	Independent Director	5.3yrs	US$298.00k	0.36% $ 126.7k
Karen Carroll	Member of Scientific Advisory Board	2.5yrs	Nessun dato	Nessun dato
Anne Wyllie	Member of Scientific Advisory Board	2.5yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di C97 sono considerati esperti (durata media dell'incarico 3.7 anni).

Co-Diagnostics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

High number of new and inexperienced directors

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Recent updates

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023)

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.20 loss in 1Q 2023)

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022)

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.043 loss in 3Q 2022)

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.083 loss in 2Q 2022)

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.34 profit in 1Q 2022)

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.45 loss per share (vs US$1.27 profit in FY 2021)

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.34 profit in 2Q 2021)

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.28 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.

Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc.

Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020)

Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$0.34 (vs US$0.54 in 2Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021

Investor sentiment improved over the past week

Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from Russell 3000E Index

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.28 (vs US$0.047 loss in 1Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS US$1.59 (vs US$0.37 loss in FY 2019)

Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021

Co-Diagnostics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Co-Diagnostics, Inc. Announces the Development of A New Point-Of-Care/At Home PCR Diagnostic Testing, Screening and Surveillance Platform

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based Covid-19 PCR Test Through Walgreens Find Care®

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. Announces CFO Chnages

New 90-day high: €16.20

Investor sentiment improved over the past week

Co-Diagnostics, Inc. Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test